trending Market Intelligence /marketintelligence/en/news-insights/trending/3oS5TpkP7l6AeYILwzJSKA2 content esgSubNav
In This List

Taro Pharmaceuticals recalls 1 lot of epilepsy drug due to cross-contamination

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Taro Pharmaceuticals recalls 1 lot of epilepsy drug due to cross-contamination

Taro Pharmaceuticals U.S.A. Inc. initiated a voluntarily recall of one lot of lamotrigine 100-milligram tablets due to cross-contamination with another drug at the manufacturing facility.

The medication is indicated for the treatment of epilepsy and bipolar disorder.

According to a Jan. 10 news release, tablets in the lot were found to have been cross-contaminated with a small amount of another drug substance called enalapril maleate.

The Hawthorne, N.Y.-based private pharmaceutical company said it did not receive any product complaints or adverse events regarding the recalled tablets.

The company said it is notifying distributors and arranging for the return of all of the recalled product under the knowledge of the U.S. Food and Drug Administration.

Taro Pharmaceuticals U.S.A. is a U.S. unit of Israel-based pharmaceutical Taro Pharmaceutical Industries Ltd.